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Long-term respiratory infections with Burkholderia cepacia complex (Bcc) bacteria in cystic
ﬁbrosis (CF) patients generally lead to a more rapid decline in lung function and, in some
cases, to a fatal necrotizing pneumonia known as the “cepacia syndrome.” Bcc bacteria
are ubiquitous in the environment and are recognized as serious opportunistic pathogens
that are virtually impossible to eradicate from the CF lung, posing a serious clinical threat.
The epidemiological survey of Bcc bacteria involved in respiratory infections at the major
Portuguese CF Treatment Center at Santa Maria Hospital, in Lisbon, has been carried out
by our research group for the past 16 years, covering over 500 clinical isolates where B.
cepacia and B. cenocepacia are the predominant species, with B. stabilis, B. contaminans,
B. dolosa, and B. multivorans also represented. The systematic and longitudinal study of
this CF population during such an extended period of time represents a unique case–study,
comprehending 41 Bcc-infected patients (29 pediatric and 12 adult) of whom around 70%
have been persistently colonized between 7months and 9 years. During chronic infection,
the CF airways represent an evolving ecosystem, with multiple phenotypic variants emerg-
ing from the clonal population and becoming established in the patients’ airways as the
result of genetic adaptation. Understanding the evolutionary mechanisms involved is cru-
cial for an improved therapeutic outcome of chronic infections in CF.This review focuses on
our contribution to the understanding of these adaptive mechanisms based on extensive
phenotypic, genotypic, and genome-wide expression approaches of selected Bcc clonal
variants obtained during long-term colonization of the CF airways.
Keywords: cystic fibrosis, chronic respiratory infection, long-term colonization, Burkholderia cepacia complex,
Burkholderia cenocepacia, genome-wide expression, clonal variation
BURKHOLDERIA CEPACIA COMPLEX BACTERIA IN CYSTIC
FIBROSIS RESPIRATORY INFECTIONS
The Burkholderia cepacia complex (Bcc) bacteria are important
opportunistic human pathogens, especially in cystic ﬁbrosis (CF)
patients (Drevinek and Mahenthiralingam, 2010). CF is an inher-
ited chronic disease,with amedian prevalence value of about 0.737
patients per 10,000 in the 27 European Union (EU) countries
(Farrell, 2008). CF is characterized by the absence of a functional
chloride transporter known as cystic ﬁbrosis transmembrane con-
ductance regulator (CFTR) that is normally present in epithelial
cell membranes, resulting in multiple organ system impairment
(Sheppard andWelsh,1999;Ratjen andDöring,2003;Gadsby et al.,
2006). CFTR plays a crucial role in regulating ﬂuid secretion by the
airways, intestines, sweat glands, and other epithelial tissues, and
the respiratory tract is one of themost profoundly affected systems
where the defect in ion transport results in accumulation of highly
viscous mucus. The resulting ineffective mucociliary clearance in
the lung leads to colonization of the airways with several bacterial
pathogens and, ultimately, to respiratory infections that are the
major cause of morbidity and mortality in individuals with CF
(Ratjen and Döring, 2003).
The large majority of respiratory infections among CF patients
are caused by Pseudomonas aeruginosa, while bacteria of the Bcc
infect a smaller fraction of these patients (Lyczak et al., 2002;
Govan et al., 2007).However,Bcc infections are particularly threat-
ening and feared by CF patients, since they give rise to a highly
variable and unpredictable clinical outcome, ranging from asymp-
tomatic carriage to a fulminating septicemiawith acute respiratory
failure known as“cepacia syndrome”(Jones et al., 2001;Mahenthi-
ralingam et al., 2005). Pulmonary colonization with Bcc is largely
associated with a worse prognosis and an increased risk of death;
consequently, Bcc-infected patients are frequently excluded from
consideration for lung transplantation (Lyczak et al., 2002). Bcc
bacteria are often resistant to most clinically used antibiotics (Fux
et al., 2005; Leitao et al., 2008). This trait and the ability to develop
high-level resistance during antibiotic treatment and to adapt and
resist to other adverse environmental conditions severely hinders
the effective treatment of Bcc respiratory infections, rendering
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their eradication from the CF lung very difﬁcult if not virtu-
ally impossible (Burns, 2007). Although a transient infection of
the respiratory tract may occur for some patients, the acquisi-
tion of Bcc most typically results in chronic infection. Bcc chronic
infections usually involve a single strain; however, prolonged co-
infection with two or more distinct strains or species and the
replacement of an initial infecting strain with another during the
course of chronic infection can also occur (Richau et al., 2000;
Cunha et al., 2003, 2007;Yang et al., 2006; Harrison, 2007; LiPuma,
2010). Furthermore, during chronic colonization of the CF air-
ways, microbial pathogens undergo widespread positive selection
across the genome (Harrison, 2007). Although recent studies have
tried to shed light on the topic of microbial evolutionwithin theCF
lung, the focus has beenmainly onP. aeruginosa (Smith et al., 2006;
Feliziani et al., 2010; Schobert and Tielen, 2010), while equivalent
studies on Bcc bacteria remain conspicuously lacking.
A 16-YEAR SYSTEMATIC STUDY OF BURKHOLDERIA
CEPACIA COMPLEX RESPIRATORY INFECTIONS IN A
PORTUGUESE CYSTIC FIBROSIS CENTER
BACKGROUND INFORMATION
In this review we aim to give a contribution to the understanding
of relevant aspects of Bcc bacteria-mediated respiratory infections
in CF patients, based on the epidemiological surveys carried out
by our research group of a case–study population that has been
routinely followed for the past 16 years at the CF Treatment Cen-
ter of Santa Maria Hospital (HSM), in Lisbon. This CF population
comprises a total of 124 patients, of which 58% are children (up
to 18 years old) and 42% are adults (Figure 1). In the CF pedi-
atric population 54% are female and 46% are male, while in
the CF adult population 58% are females and 42% males. Bcc
bacteria have been isolated from 41 of these patients, belonging to
both the adult (n = 12) and pediatric (n = 29) populations. The
age at the time of the ﬁrst Bcc isolation varied between a few
months of life and 28 years old, with an estimated mean age of
10 years.
Studies involving the use of B. cenocepacia isolates collected
from CF patients at HSM were approved by the ethics committee
of the Hospital, and the anonymity of the patients is preserved.
PREVALENCE OF DIFFERENT Bcc SPECIES
The CF subpopulation is represented by a collection of 506 Bcc
clinical isolates and clonal variants that were gathered during
our 16-year collaboration with the HSM CF Center. This collec-
tion includes serial isolates recovered from persistently colonized
patients from the early to late stages of infection. According to this
routine, sputum samples are obtained from CF patients every 2–
3months, during periodic consultations to monitor their clinical
status, or more often for patients showing clinical deterioration
(Cunha et al., 2007). The systematic molecular analysis of the 506
isolates revealed that the most prevalent Bcc species recovered
from the sputa of the 41 Bcc-infected patients are B. cepacia and
B. cenocepacia (Figure 2A).
While B. cepacia is not a predominant Bcc species among the
CF population characterized worldwide (Mahenthiralingam and
Vandamme, 2005), detailed molecular analysis unveiled an excep-
tionally high incidence of B. cepacia at the HSM CF Center from
2003 to 2005 (Figure 2B), with isolates being retrieved from 11
out of 13 Bcc-infected patients (Cunha et al., 2007). This abnor-
mal prevalence of B. cepacia was associated with two B. cepacia
clones that were indistinguishable from two strains isolated from
contaminated non-sterile saline solutions for nasal application,
detected during routine market surveillance by the Portuguese
Medicines and Health Products Authority, INFARMED (Cunha
et al., 2007). After this contamination was detected, the number of
B. cepacia isolates identiﬁed at HSM gradually declined over the
following years, although still remaining signiﬁcantly high due to
persistent colonization of the living patients (Figure 2B). Inter-
estingly, 2005 coincides with a peak in the number of CF patients
with newly detected Bcc infections (Figure 2C). Although trans-
mission of Bcc bacteria is considered an important factor in the
colonization of CF patients, other primary sources of infection
must be taken into account in CF centers where the recommended
control measures are followed, as is the case of the CF center at
HSM. It is likely that the environment might act as a reservoir
for novel Bcc infections (Pallud et al., 2001; LiPuma et al., 2002;
Vanlaere et al., 2005), and attention should be given to continuous
monitoring of medication for microbial contaminations. Indeed,
Bcc bacteria are resistant to multiple antimicrobials and to diverse
growth inhibitors that can even be used as carbon sources (Coenye
and Vandamme, 2003). Since these bacteria also have minimal
nutritional requirements, they are able to grow in aqueous prod-
ucts, including disinfectants (Oie and Kamiya, 1996; Ghazal et al.,
2006). Contamination of albuterol and sulbutamol nebulization
solutions (Balkhy et al., 2005; Ghazal et al., 2006), nebulizers
(Hutchinson et al., 1996), mouthwash (Matrician et al., 2000),
nasal sprays (Dolan et al., 2005), and ultrasound gel (Jacobson
et al., 2006) have resulted in outbreaks of nosocomial infections
by Bcc bacteria. Therefore, the surveillance of unexplained out-
breaks of less common pathogens is essential; in particular, those
involving poorly represented species, like B. cepacia, especially in
patients with underlying lung disease and increased risk such as
CF patients.
In addition to B. cenocepacia and B. cepacia, four other Bcc
species have been isolated from the HSM CF population: B. dolosa,
B. contaminans, B. stabilis, and B. multivorans (Cunha et al., 2003,
2007, unpublished results; Figures 2A,B,D). Because the taxon-
omy of Bcc bacteria evolved signiﬁcantly in the last few years, with
the description of eight novel species (Vanlaere et al., 2008, 2009),
we have re-examined the species identiﬁcation of several isolates
from our collection. We paid special attention to isolates that were
classiﬁed as B. cepacia with recA-RFLP proﬁle K (Cunha et al.,
2003, 2007), since this taxon was recently shown to comprise at
least two novel species (Vanlaere et al., 2009), and the multilocus
sequence typing (MLST) analysis revealed that several of those
isolates now belong to the B. contaminans species. Co-infection
with two or three different Bcc species was also observed in nine
patients, mainly involving B. cenocepacia and B. cepacia, and in a
smaller percentage with B. cenocepacia and B. contaminans, with
B. cenocepacia, B. stabilis, and B. multivorans, or with B. cenocepa-
cia and B. dolosa (Figure 2D). Although there is a generalized
idea that B. cenocepacia is associated with greater morbidity and
mortality in CF patients (Speert, 2002; Mahenthiralingam et al.,
2005), epidemiological surveys show that all of the species above
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FIGURE 1 | Characterization of the CF subpopulation that has been
monitored at the major Portuguese CFTreatment Center at Santa Maria
Hospital, in Lisbon, for the past 16 years.The population was characterized
in terms of gender, age, type of colonization, and clinical outcome. Among the
deceased patients, at least ﬁve had developed the cepacia syndrome at the
time of death (each patient marked as ∗). Based on the information published
in Richau et al. (2000), Cunha et al. (2003, 2007), and on other recent
unpublished data.
are associated with poor clinical outcome, including the cepacia
syndrome, and give rise to chronic and transient infections (Cunha
et al., 2003, 2007; Drevinek and Mahenthiralingam, 2010). In fact,
it is not clear why strains of different Bcc species differ in their
persistence, epidemiology, and pathogenic potential in CF, or why
the same strain can be associated with very different clinical out-
comes. It probably depends on factors that are inherent to each
individual patient, on co-colonization by other pathogens and on
other still unidentiﬁed factors.
PREVALENCE OF CHRONIC AND TRANSIENT INFECTIONS
Patients were characterized as persistently colonized with Bcc if
at least three positive cultures for these bacteria were recovered
during a 6-month period (Cunha et al., 2007). According to this
criterion, approximately 68% of the 41 Bcc-infected patients were
persistently colonized (9 adults and 19 children), for time periods
ranging from 7months to almost 10 years, while the remain-
ing 32% registered only intermittent isolation (Figure 2E). The
majority of the Bcc isolates from our collection are serial isolates
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FIGURE 2 | Profiling of the Bcc-infected CF subpopulation. (A)
Distribution of the Bcc clinical isolates into the corresponding Bcc species;
(B) Chronological distribution of the different Bcc species isolates; (C)
Number of patients and date of ﬁrst Bcc positive isolation
(pediatric – white bars and adults – black bars); (D) Number of patients
infected with the different species, including co-infection (cen – B.
cenocepacia; cep – B. cepacia; stab – B. stabilis; mult – B. multivorans;
cont – B. contaminans; dol – B. dolosa); (E) Period of duration of chronic
infection and clinical outcome (eradication – white bars, death – black bars,
∗ denotes a conﬁrmed cepacia syndrome). Based on the information
published in Richau et al. (2000), Cunha et al. (2003, 2007), and on other
recent unpublished data.
retrieved from these persistently colonized patients, of whom 12
have died during the past 16 years. At least ﬁve patients devel-
oped a conﬁrmed cepacia syndrome at the time of death, and four
were female. When analyzing the clinical outcome of both the
adult andpediatric subpopulations of chronically infected patients
(Figure 1), it is clear that the worst outcomes lye in the female
subpopulation. Within the adult group, all female patients have
either died or have a clinically deteriorated status, while 40% of
the male patients have either eradicated the bacteria or are stable.
Among the pediatric patients, there is a mixed tendency, with a
worse outcome for girls in terms of death or clinical deterioration,
but with 50% of stable or eradicated cases. Interestingly, a female
disadvantage regarding a worse prognosis and impaired survival
in the course of CF has been documented for years (Kerem et al.,
1992;Dodge et al., 1993; FitzSimmons, 1993; Rosenfeld et al., 1997;
Fogarty et al., 2000; O’Connor et al., 2003; Barr et al., 2011; Taylor-
Robinson and Schechter, 2011). This so-called gender gap has been
insufﬁciently explained by a series of risk factors in female patients,
including a higher prevalence of CF-related diabetes (Adler et al.,
2008), reduced activity levels (Selvadurai et al., 2004), a prepon-
derance for early acquisition of P. aeruginosa and Bcc bacteria
(Demko et al., 1995; Olesen et al., 2010; Sawicki et al., 2011), and
estrogens (Coakley et al., 2008; Zeitlin, 2008; Tam et al., 2011).
Most of these factors can bemitigated by the development of mod-
ern treatments and standardized intensive care (Verma et al., 2005;
Viviani et al., 2011), but the importance of female sex hormones
is currently being highlighted by several studies (Coakley et al.,
2008; Zeitlin, 2008; Tam et al., 2011). Estrogen has been shown to
aggravate P. aeruginosa inﬂammation in CF mice models (Wang
et al., 2010), and in the human lung it has been suggested to aug-
ment mucin production (Tam et al., 2011) and impair mucociliary
clearance (Coakley et al., 2008; Chotirmall et al., 2010). In fact, 17-
beta-estradiol was shown to inhibit the CFTR-alternative chloride
transporter, especially around ovulation, and this might account
for one of themore intrinsic factors in the gender gap of CF (Coak-
ley et al., 2008). Looking back at our pediatric female population,
and taking into account that it includes girls up to 18 years old,
we observe that all of the nine patients who have eradicated the
bacteria or are currently stable are 12 years old or less, an age that
is usually before puberty.
ADAPTATION WITHIN THE LUNG OF CF PATIENTS
CLONAL PHENOTYPIC VARIATION OF Bcc DURING LONG-TERM
COLONIZATION OF THE LUNGS OF A CF PATIENT
During chronic infection of the lung, opportunistic bacterial
pathogens within the CF airways evolve in response to stressing
selection pressures exerted by the host environment, in partic-
ular those resulting from challenges of the immune defenses,
antimicrobial therapy, nutrient availability, and oxygen limita-
tion (Harrison, 2007; Hogardt and Heesemann, 2010; Doring
et al., 2011). This leads to the emergence of phenotypic vari-
ants of the underlying clonal population that exhibit different
antimicrobial susceptibility patterns, size of the bioﬁlms formed,
and other critical phenotypic differences in the context of bacterial
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pathogenesis (Mahenthiralingam et al., 2002; Cunha et al., 2004,
2007; Smith et al., 2006; Leitao et al., 2008; Coutinho et al., 2011).
The occurrence of clonal expansion of B. cenocepacia during long-
term colonization of a CF patient was recently shown to occur
(Coutinho et al., 2011), but studies on the mechanisms of Bcc
bacterial evolution within the CF airways are still in need. A better
understanding of how Bcc bacteria adapt to the CF lung environ-
ment while resisting host defense mechanisms and therapeutically
administered antibiotics is crucial to deal with these chronic infec-
tions. Our group has given a contribution to this ﬁeld, based on
phenotypic and genome-wide expression analyses of serial Bcc
clonal variants obtained during infection of CF patients (Moreira
et al., 2003; Leitao et al., 2008; Ramos et al., 2010; Coutinho et al.,
2011; Madeira et al., 2011; Silva et al., 2011).
The results of a systematic phenotypic assessment of 11 B. ceno-
cepacia sequential isolates (Coutinho et al., 2011), retrieved from
the same CF patient sputum during a period of chronic infection,
are consistent with the idea that the CF lung can be persistently
infected for years by one or more lineages of Bcc (or P. aeruginosa)
species with development of clonal expansion (Cunha et al., 2003,
2007; Govan et al., 2007; Drevinek and Mahenthiralingam, 2010).
The patient under study (patient J) was chronically colonized with
the same strain during three and half years until death with the
cepacia syndrome. The clonal nature of the 11 isolates was demon-
strated based on recA-RFLP,EcoRI ribopattern (Cunha et al., 2003;
Coutinho et al., 2011), and MLST proﬁling (Cunha et al., 2003;
Coutinho et al., 2011). Moreover, the MLST analysis revealed that
four of the isolates exhibited a new allelic proﬁle. Although they
are not identical clones, all isolates are part of the same clonal
Based Upon Related Sequence Types (BURST) group (Coutinho
et al., 2011). The phenotypic traits related to bacterial persistence
and pathogenicity that were assessed include susceptibility against
different classes of antimicrobials, growth efﬁciency under iron
limitation, colony and cell morphology, exopolysaccharide pro-
duction, size of the bioﬁlms formed, etc. (Coutinho et al., 2011).
Interestingly, the more resistant Bcc clonal variants were isolated
following pulmonary exacerbation and aggressive antibiotic ther-
apy (Leitao et al., 2008; Coutinho et al., 2011), suggesting that
antibiotic stress drives the emergence of resistant populations of
B. cenocepacia isolates.
In general, the properties of the isolate believed to have initi-
ated the infection differ signiﬁcantly from those exhibited by the
isolates obtained during the course of infection (Coutinho et al.,
2011). Bacteria are able to grow to high densities in theCF lung in a
mucopurulent material that is limited or depleted in oxygen (Wor-
litzsch et al., 2002), and, until recently, it was generally accepted
that P. aeruginosa used nitrate-based anaerobic respiration as the
primary mode of growth during chronic infections (Yoon et al.,
2002). However, recent studies have demonstrated that P. aerugi-
nosa is well adapted to these oxygen-depleted conditions, and that
its predominant mode of growth in the CF lung is microaerobic
respiration, probably in concert with nitrate respiration (Alvarez-
Ortega andHarwood,2007;Hoffman et al., 2010).Very lowoxygen
availability is currently recognized as an important factor con-
tributing to antibiotic resistance and persistent infections of P.
aeruginosa in the CF airways (Hoffman et al., 2010; Schobert and
Tielen, 2010), but little is known about the underlying molecular
mechanisms. However, it appears that the adaptation process in
this species predominantly affects metabolic pathways, in par-
ticular those involving metabolism of fatty acids, amino acids,
and generation of energy (Hoboth et al., 2009). The reduction of
membrane fatty acid saturation degree was recently described by
our group as an adaptive response of B. cenocepacia to growth
under severe oxygen-depleted conditions (Coutinho et al., 2011).
Notably, the isolates retrieved during the last 10months of patient
J’s life evidenced a clear time-dependent decrease of the level of
fatty acid saturation that was associated with the depletion of oxy-
gen in the CF lung that accompanies disease progression and the
deterioration of lung function (Coutinho et al., 2011). The rele-
vance of the observed reduction in the saturation fatty acid degree
for growth of B. cenocepacia bacteria under microaerophilic con-
ditions is currently being investigated in our laboratory, as well as
equivalent studies for CF clinical isolates belonging to other Bcc
species.
Iron-acquisition mechanisms are key factors for the successful
colonization of human infecting bacteria, since the level of free
iron within mammals is well below the one required for optimal
bacterial growth (Ratledge and Dover, 2000). The importance of
iron homeostasis and of its role in determining the success and
chronicity of P. aeruginosa infections is well documented (Reid
et al., 2007, 2009), and there are evidences that Bcc bacteria can
alter P. aeruginosa physiology and induce several iron-responsive
genes through a mechanism that involves iron sequestration by
ornibactin (Weaver and Kolter, 2004). As expected, the ﬁrst B.
cenocepacia isolate that was retrieved during long-term infection
of patient J is less suited to grow under iron limitation than most
of the subsequent isolates (Coutinho et al., 2011).
Based on the population that was previously characterized
at the species and ribopattern levels (Cunha et al., 2003, 2007),
we have applied a methodology for the rapid discrimination
of Bcc clinical isolates, using Fourier-transform infrared spec-
troscopy (FTIR) and chemometric analyses (Coutinho et al.,
2009). This methodology was found to discriminate between
clonal isolates belonging to the same species and exhibiting the
same ribopattern (Coutinho et al., 2009, unpublished results).
The more prominent differences registered in the FTIR spectral
analyses of the clonal variants examined were observed in the
1500–900 cm−1 range, a spectral region that corresponds to poly-
saccharide, phospholipid, and DNA/RNA molecular vibrations.
The whole-bacteria infrared spectral analysis provided by this
FTIR-based approach has the potential to be used in Hospitals
for the rapid identiﬁcation of chemical modiﬁcations occurring at
the bacterial cell surface that may be clinically relevant, including
alterations occurring at the level of lipopolysaccharide (LPS) struc-
ture, polyhydroxyalkanoates family compounds, lipoproteins, and
phospholipids.
APPLICATION OF OMICS APPROACHES TO ELUCIDATE Bcc ADAPTIVE
STRATEGIES TO THE CF LUNG
More recently, we have explored OMICS approaches to investi-
gate the adaptive molecular strategies of Bcc bacteria in the CF
lung at a molecular systems biology level, based on quantitative
proteomics and microarrays analyses (Madeira et al., 2011; Mira
et al., 2011). Other OMICS approaches that have been used in
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this context include metabolomics (Behrends et al., 2011; Fang
et al., 2011) and the screening of genomic libraries (Moreira et al.,
2003; Subsin et al., 2007; Ramos et al., 2010). Metabolomics have
been successfully used to study mechanisms of osmotic tolerance
in B. cenocepacia (Behrends et al., 2011) and to reconstruct the
metabolic network of B. cenocepacia J2315, resulting in the iden-
tiﬁcation of new potential therapeutic targets (Fang et al., 2011).
The generation of mutant libraries from B. cenocepacia and B.
cepacia strains by random mutagenesis with plasposons led to
the identiﬁcation of the pleiotropic regulator Pbr as a stress resis-
tance and virulence determinant (Ramos et al., 2010). A similar
approach allowed the identiﬁcation of the gene cluster associ-
ated with biosynthesis of the cepacian exopolysaccharide and of
the involvement of exopolysaccharide production in the size of
the bioﬁlms formed (Moreira et al., 2003; Cunha et al., 2004).
Mutant libraries have also been used to identify genes contribut-
ing to increased persistence and virulence of B. cenocepacia in
the lungs of CF rat models (Hunt et al., 2004; Bernier and Sokol,
2005). An alternative application of genomic libraries described
the screening of a random promoter library of B. cenocepacia,
which enabled the identiﬁcation of genes regulated by the cepIR
quorum-sensing system (Subsin et al., 2007). The exploitation of
OMICS approaches such as phenotypic screens, transcriptomics,
proteomics, andmetabolomics has been instrumental to getmech-
anistic insights into the global strategies used by Bcc bacteria to
adapt to long-term residence in the stressing environment of the
CF lung under antimicrobial therapy. Moreover, the genes and
proteins identiﬁed represent interesting potential targets for inac-
tivation to enhance antimicrobial activity and to limit colonization
by Bcc bacteria.
In this context, the genomic expression of 2 of the 11 B. ceno-
cepacia sequential clonal variants from patient J were compared in
our laboratory: IST439, the ﬁrst isolate that was collected from the
patient and is thought to have initiated the infection, and IST4113,
an isolate that was recovered almost 3 years later after a period of
exacerbated infection and intravenous therapy with gentamicin
and ceftazidime (IST4113; Figure 3; Cunha et al., 2003; Coutinho
et al., 2011; Madeira et al., 2011; Mira et al., 2011). Among other
phenotypic differences, the IST4113 isolate was found to be much
more resistant than IST439 to all the tested antibiotics belonging to
different classes and having distinct biological targets (Figure 3A;
Coutinho et al., 2011; Madeira et al., 2011). The proteome and
transcriptome of IST439 and of the highly antibiotic-resistant
clonal variant IST4113 were compared using a quantitative pro-
teomics approach based on 2D difference gel electrophoresis
(DIGE; Madeira et al., 2011) and custom-made DNA microar-
rays (Mira et al., 2011 and Drevinek et al., 2008). The cells used for
these two genome-wide analyses were cultivated for 24 h at 37˚C
on the surface of LB solid medium, an experimental setup that
mimics the surface-attached bacterial growth expected to occur
during chronic colonization of the CF lung. The results of the
two studies were complementary, even though the limited protein
coverage of the quantitative DIGE-based approach (79 proteins
identiﬁed) failed to identify a number of relevant gene expression
differences that emerged in the transcriptomic analysis, in partic-
ular involving functional groups whose identiﬁcation is difﬁcult
to achieve using quantitative proteomics (e.g., transmembrane
FIGURE 3 | Phenotypic characteristics of the B. cenocepacia clonal
variants IST439 and IST4113, retrieved from the same CF patient
sputum during long-term residence in the lung and whose genomic
expression was compared by quantitative proteomic and
transcriptomic analyses. (A) Minimum inhibitory concentration (MIC)
values; (B) Growth of IST439 and IST4113 under limited or load iron
conditions; (C) Fatty acid saturation of the clonal variants obtained during
the 41-months of chronic colonization; (D) Colony morphology; (E) Amount
of bioﬁlms formed based on crystal violet method; (F) Swarming and
swimming motilities; (G) Zeta potential; (H) Cell size; (I) Exopolysaccharide
produced; (J) Fraction of cells at the interface of water and n-hexadecane.
Based on results from Coutinho et al. (2011) and Madeira et al. (2011).
solute transporters) and low expressed genes/proteins. We iden-
tiﬁed approximately 1000 genes that are differentially expressed
in IST439 and IST4113, reﬂecting a marked reprogramming of B.
cenocepacia genomic expression occurring alongside disease pro-
gression and clinical deterioration of the patient, similarly to what
has been described for P. aeruginosa (Spencer et al., 2003; Hoboth
et al., 2009; Yang et al., 2011). In general, the functional classes
enriched in the datasets of differently abundant proteins or tran-
scripts in the two isolates coincided, with several genes/proteins
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associated with carbohydrate and amino acid metabolism, trans-
lation, iron uptake, nucleotide synthesis, and protein folding being
identiﬁed as up-regulated in IST4113 (Madeira et al., 2011; Mira
et al., 2011).
Several of the observations that emerged from the transcrip-
tomic and proteomic analyses are consistent with the previ-
ously carried out phenotypic characterization of the two isolates
(Figure 3; Coutinho et al., 2011), and are suggestive of genetic
adaptation from isolate IST439 to IST4113. For example, the up-
regulation of proteins and genes associated with iron binding and
transport in IST4113 cells (Madeira et al., 2011;Mira et al., 2011) is
in line with the higher efﬁciency that these cells exhibit to recover
iron froman iron-limited environment,when compared to IST439
cells (Figure 3B; Coutinho et al., 2011; Madeira et al., 2011).
Notably, a higher capacity to scavenge iron is an adaptive trait
that contributes to increase bacterial persistence in the CF lung
(Reid et al., 2007, 2009).
The up-regulation of many proteins/genes related with protein
synthesis, translation, and protein folding in the IST4113 isolate
might also contribute to the higher resistance exhibited by IST4113
against antimicrobials targeting protein synthesis (Figure 3A;
Leitao et al., 2008; Coutinho et al., 2011; Madeira et al., 2011),
which include the aminoglycosides gentamicin and tobramycin
(Jana and Deb, 2006). This marked representation of protein syn-
thesis processes in IST4113 could represent a molecular adaptive
strategy to overcome the inhibitory effect of the gentamicin intra-
venous therapy given to the patient just before the isolation of
IST4113. Alterations observed at the level of LPS structure and/or
content, cell wall, and outer membrane biogenesis are also con-
sistent with the highly antibiotic-resistant phenotype of IST4113
cells (Figure 3A). Our results suggest that proteins involved in
lipid A and O-antigen formation (two biologically active compo-
nents of the Bcc LPS) are less expressed in IST4113 (Madeira et al.,
2011), which might reﬂect an adaptive strategy that contributes to
protection from the host immune system. In fact, sensing of lipid
A has been shown to have a potent pro-inﬂammatory effect, lead-
ing to the onset of immune responses to Bcc infections (De Soyza
et al., 2004; Silipo et al., 2007), while O-antigen deﬁciency has
been suggested to contribute to enhanced B. cenocepacia adhesion
to bronchial epithelial cells (Saldias et al., 2009). Lower content
of the O-antigen has also been associated with a rough colony
morphotype (Saldias et al., 2009), an hypothesis that is consis-
tent with the rough colonies formed by IST4113 whereas IST439
cells possess a smooth colony morphotype (Figure 3D; Coutinho
et al., 2011; Madeira et al., 2011). Our results also suggest that the
content of several outer membrane proteins is lower in IST4113
than in IST439, including several porines that are signiﬁcantly
down-regulated (Madeira et al., 2011; Mira et al., 2011). The
outer membrane in Gram-negative bacteria acts as a barrier for
resistance to most antimicrobial agents (Nikaido, 2003), and the
reduction of outer membrane porines has been described as an
importantmechanism tomaintain the impermeability of the outer
membrane and improve antibiotic resistance in Gram-negative
bacteria (Moore and Hancock, 1986; Aronoff, 1988; Burns, 2007).
At least three of the down-regulated porines in IST4113 are close
homologs of porines of other Gram-negative bacteria (including
B. cepacia) that have been shown tomediate the entry of antibiotics
into the intracellular environment (Moore and Hancock, 1986;
Aronoff, 1988; Burns, 2007). IST4113 also possesses higher tran-
script levels of various drug efﬂux pumps-encoding genes, which
is consistent with the higher active drug export capacity exhib-
ited by these cells when compared to IST439 (Mira et al., 2011).
A global overview of the transcriptomic results further shows that
alterations related with adaptation to the nutritional microenvi-
ronment of theCF lung, in particular at the level of amino acid and
energy generation metabolism, is a key feature of the transcrip-
tional reprogramming that characterizes this chronic infection,
consistent with the recently established link between metabolism
and microbial pathogenicity (Hoffman et al., 2010; Rohmer et al.,
2011).
FINAL REMARKS
For the past 16 years, our group has carried out epidemiological
surveys of Bcc bacteria involved in respiratory infections at the
HSM CF Treatment Center in Lisbon. This resulted in a system-
atic and longitudinal characterization of 41 Bcc-infected patients,
represented by a collection of over 500 clinical isolates retrieved
during the patient care routine followed at the hospital. Several of
these patients were chronically infected for years, and during that
time the bacterial population was subjected to changing selection
pressures that led to the development of clonal expansion and
emergence of phenotypic variants. To improve our knowledge of
the mechanisms behind the underlying genetic adaptation and its
impact on bacterial colonization and persistent infection by Bcc
bacteria, we have carried out phenotypic and molecular biology
analyses of Bcc clinical isolates, as well as genome-wide expression
approaches. Genetic adaptation to the stressing conditions of the
CF lung, leading to higher antibiotic resistance and bacterial per-
sistence during chronic infection, is suggested by the comparison
of the proteomes and transcriptomes of the clonal variants exam-
ined. A working model summarizing the most signiﬁcant ﬁndings
suggested by our studies and described in this review is proposed
in Figure 4. Although the results emerging from these studies pro-
vide an important contribution to the current understanding of
the adaptive mechanisms employed by B. cenocepacia to chroni-
cally colonize the lungs of CF patients, it should be emphasized
that the isolates examined were randomly selected from a broader
heterogeneous colonizing population and thus it is not known
how much of the observed responses are representative of the
adaptive responses of the entire colonizing population. To elu-
cidate this matter, we are currently extending the OMICS-based
studies herein described to other sequential isolates of B. cenocepa-
cia and of other Bcc species obtained from different CF patients.
Speciﬁc effects exerted by environmental conditions with rele-
vance in the context of CF infections and long-term colonization
of the CF lung, such as low oxygen concentrations, are also being
examined.
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